Our Science

OUR SCIENCE

Congress Presentations

This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.


ESMO-BC 2023 | Berlin, Germany

May 11 - 13, 2023

Poster
VERITAC Update: Phase 2 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast Cancer

SA Hurvitz et al.

ESMO-BC 2023 | Berlin, Germany

May 11 - 13, 2023

Poster
TACTIVE-E: Phase 1b Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination with Everolimus in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast Cancer

A Philipovskiy et al.

ESMO-BC 2023 | Berlin, Germany

May 11 - 13, 2023

Poster
VERITAC-2: A Global, Randomized Phase 3 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast Cancer

EP Hamilton et al.

CSHL Ubiquitins, Autophagy & Disease 2023 | Cold Spring Harbor, NY

Apr 25 - 29, 2023

Presentation
Small Molecule PROTAC® Hijacking and Structural Characterization of an E3 Ligase, KLHDC2, for Targeted Protein Degradation

K Digianantonio

AACR 2023 | Orlando, FL

Apr 14 - 19, 2023

Presentation
Discovery of ARV-766, an Androgen Receptor Degrading PROTAC® for the Treatment of Men with Metastatic Castration Resistant Prostate Cancer

LB Snyder

AACR 2023 | Orlando, FL

Apr 14 - 19, 2023

Poster
Mechanisms of Acquired Resistance to ARV-471, a Novel PROTAC® Estrogen Receptor Degrader

J Teh et al.

AACR 2023 | Orlando, FL

Apr 14 - 19, 2023

Poster
Enhanced Efficacy of ARV-471, a Novel PROTAC® Estrogen Receptor Degrader, in Combination with Targeted Agents in Estrogen Receptor-Positive (ER+) Breast Cancer Models

J Teh et al.

ACS Spring 2023 | Indianapolis, IN

Mar 26 - 30, 2023

Presentation
The Arvinas PROTAC® Discovery Engine: PROTAC® Biophysical Characterization Fuels The Discovery Of Target And E3 Ligase Ligands For Optimized PROTAC® Degrader Molecules

A Harbin

AACR Special Conference: Targeting RAS 2023 | Philadelphia, PA

Mar 5 - 8, 2023

Presentation
KRAS-Targeted PROTAC® Degraders Are Broadly Efficacious Against KRAS Dependent Tumor Models

K Smith